Pulmonx Co. (NASDAQ:LUNG) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Pulmonx Co. (NASDAQ:LUNG) has been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $14.67.

A number of equities analysts recently weighed in on LUNG shares. Canaccord Genuity Group boosted their price target on shares of Pulmonx from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Wells Fargo & Company lowered their target price on shares of Pulmonx from $14.00 to $10.00 and set an “equal weight” rating for the company in a research note on Thursday, August 1st. Finally, Stifel Nicolaus dropped their price objective on Pulmonx from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Thursday, October 31st.

Pulmonx Stock Performance

NASDAQ LUNG opened at $6.79 on Friday. Pulmonx has a twelve month low of $5.46 and a twelve month high of $14.84. The stock has a market capitalization of $268.14 million, a price-to-earnings ratio of -4.62 and a beta of 0.68. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The stock has a 50-day moving average of $7.07 and a 200 day moving average of $7.14.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings results on Wednesday, October 30th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. The firm had revenue of $20.39 million for the quarter, compared to analyst estimates of $20.39 million. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. During the same period last year, the company posted ($0.39) EPS. Sell-side analysts anticipate that Pulmonx will post -1.53 EPS for the current fiscal year.

Insider Transactions at Pulmonx

In other news, General Counsel David Aaron Lehman sold 5,765 shares of Pulmonx stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $6.69, for a total value of $38,567.85. Following the transaction, the general counsel now directly owns 203,348 shares of the company’s stock, valued at $1,360,398.12. The trade was a 2.76 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Glendon E. French III sold 20,000 shares of Pulmonx stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $8.09, for a total transaction of $161,800.00. Following the completion of the transaction, the director now owns 1,111,974 shares in the company, valued at approximately $8,995,869.66. This represents a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 50,351 shares of company stock valued at $361,494. Insiders own 5.70% of the company’s stock.

Institutional Trading of Pulmonx

A number of hedge funds have recently added to or reduced their stakes in LUNG. FMR LLC raised its position in Pulmonx by 11.2% during the 3rd quarter. FMR LLC now owns 5,872,882 shares of the company’s stock worth $48,686,000 after buying an additional 591,859 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Pulmonx by 0.6% in the first quarter. Vanguard Group Inc. now owns 2,077,859 shares of the company’s stock valued at $19,262,000 after purchasing an additional 11,417 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in Pulmonx by 5.2% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,114,297 shares of the company’s stock valued at $9,238,000 after buying an additional 55,279 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Pulmonx by 1.3% during the third quarter. Geode Capital Management LLC now owns 892,786 shares of the company’s stock valued at $7,403,000 after acquiring an additional 11,151 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its stake in shares of Pulmonx by 1.0% during the 2nd quarter. Victory Capital Management Inc. now owns 834,301 shares of the company’s stock worth $5,289,000 after purchasing an additional 8,004 shares during the last quarter. 91.04% of the stock is owned by institutional investors and hedge funds.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.